Vincamine

Vincamine is a peripheral vasodilator, that increases blood flow to the brain. (In Vitro) :Vincamine (20, 40 and 80 μM; 24 hours) exerts a signi cant, concentration-dependent protective effect in LPS-treated human corneal epithelial cells (HCECs) cells.Vincamine (20, 40 and 80 μM; 24 hours) significantly reduces ROS level in a dose-dependent manner in LPS-treated human corneal epithelial cells (HCECs) cells. Additionally, after Vincamine administration, the levels of MDA is also significantly reduced while the levels of T-AOC, and SOD are increased in a dose-dependent manner.Vincamine (20, 40 and 80 μM; 24 hours) rescues TrxR activity in a dose-dependent manner in HCECs. However, the intracellular activities of Trx, GR and GPx are neither inhibited nor activated by both LPS and Vincaminer.Vincamine could activate GPR40 (EC50=6.28 μM) with DHA (GPR40 ligand) as a positive control (EC50=3.85 μM) in hGPR40-CHO cells. (In Vivo) :Vincamine (intraperitoneal injection; 15 and 30 mg/kg/day; 6 weeks) improves glucose tolerance in type 2 diabetic model mice. It effectively lowers the levels of fasting blood glucose and glycated hemoglobin. At the same time, it ameliorates oral glucose tolerance and elevated glucose-induced plasma insulin concentration without influence on basal insulin secretion in vivo.

1617-90-9

Angiopac | Devincan | Equipur | Minorin | NSC 91998 | Novicet

Pharmacology & Drug Discovery

>98% (HPLC)

Water: 62 mg/L

O[C@@] (C1) (C (OC) =O) N2C3=C (C=CC=C3) C4=C2[C@@] ([C@@]1 (CC) CCC5) ([H]) N5CC4

C21H26N2O3

354.44

Storage temperature: -20°C. Stability: ≥ 2 years

For research use only.